Skip to main content
Log in

Pharmacokinetics of the time-dependent elimination of all-trans-retinoic acid in rats

  • Published:
AAPS PharmSci Aims and scope Submit manuscript

Abstract

The time-dependent elimination kinetics of all-transretinoic acid (ATRA) has been associated with autoinduction of its metabolism and has led to the hypothesis that rapid development of acquired clinical resistance to ATRA may be prevented by coadministration of metabolic inhibitors. This study in rats was performed to investigate the pharmacokinetics and onset of timedependent elimination of ATRA, with the purpose of establishing an animal model suitable for in vivo preclinical studies of compounds capable of inhibiting ATRA metabolism. After the intravenous (IV) bolus administration of single doses of ATRA (1.60 mg kg−1 and 0.40 mg kg−1), the plasma concentration-time curves showed an accelerated decline at 180 minutes after dosing. The plasma clearance (Cl) of ATRA, determined after IV administration of a second dose (1.60 mg kg−1), at 180 minutes was greater than Cl after a single dose, thus indicating the existence of a time-dependent elimination process detectable 180 minutes after administration of the first dose. Such time-dependent elimination was confirmed by means of an IV constant-rate infusion of 0.48 mg h−1 kg−1 of ATRA during 10 hours. Peak plasma ATRA concentration was achieved at 180 minutes, after which the plasma concentration decreased to reach a much lower apparent steady-state drug concentration at 420 minutes. The area under the plasma concentration-time curve (AUC) obtained after oral administration of a second ATRA dose (1.60 mg kg−1) was ∼8% of the AUC obtained after a single oral dose; consistent with a time-dependent increase in the elimination of ATRA, as was observed after IV administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Degos L, Wang ZY. All trans retioic acid in acute promyelocytic leukemia. Oncogene. 2001;20:7140–7145.

    Article  CAS  PubMed  Google Scholar 

  2. Fenaux P, Chomienne C, Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol. 2001;38:13–25.

    Article  CAS  PubMed  Google Scholar 

  3. Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am. 2001;15:867–910.

    Article  CAS  PubMed  Google Scholar 

  4. Camacho LH. Clinical applications of retinoids in cancer medicine. J Biol Regul Homeost Agents. 2003;17:98–114.

    CAS  PubMed  Google Scholar 

  5. Conley BA, Egorin MJ, Sridhara R, et al. Van echo DA. Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol. 1997;39:291–299.

    Article  CAS  PubMed  Google Scholar 

  6. Reynolds CP. Differentiating agents in pediatric malignancies: retinoids in neuroblastoma. Curr Oncol Rep. 2000;2:511–518.

    Article  CAS  PubMed  Google Scholar 

  7. Todesco A, Carli M, Iacoma I, Frascella E, Ninfo V, Rosolen A. All-trans retinoic acid and interferon-alpha in the treatment of a patient with resistant metastatic osteosarcoma. Cancer. 2000;89:2661–2666.

    Article  CAS  PubMed  Google Scholar 

  8. Goncalves A, Camerlo J, Bun H, et al. Phase II study of a combination of cisplatin, all-trans-retinoic acid and interferon-alpha in squamous cell carcinoma: clinical results and pharmacokinetics. Anticancer Res. 2001;21:1431–1437.

    CAS  PubMed  Google Scholar 

  9. Goldberg JS, Vargas M, Rosmarin AS, et al. Phase I trial of interferon alpha 2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma. Cancer. 2002;95:1220–1227.

    Article  CAS  PubMed  Google Scholar 

  10. Adamson PC, Bailey J, Pluda J, et al. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol. 1995;13:1238–1241.

    CAS  PubMed  Google Scholar 

  11. Adamson PC, Reaman G, Finklestein JZ, Feusner J, Berg SL, Blaney SM, O brien M, Murphy RF, Balis, FM. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. J Clin Oncol. 1997;15:3330–3337.

    CAS  PubMed  Google Scholar 

  12. Regazzi MB, Iacona I, Gervasutti C, Lazzarino M, Toma S. Clinical pharmacokinetics of tretinoin. Clin Pharmacokinet. 1997;32:382–402.

    Article  CAS  PubMed  Google Scholar 

  13. Gallagher RE. Retinoic acid resistance in acute promyelocytic leukemia. leukemia. 2002;16(10):1940–1958.

    Article  CAS  PubMed  Google Scholar 

  14. Torres-Molina F, Peris JE, Garcia-Carbonell MC, Aristorena JC, Granero L, Chesa-Jimenez J. Use of rats chronically cannulated in the jugular vein and the duodenum in pharmacokinetic studies. Effect of ether anesthesia on absorption of amoxicillin. Arzneimittelforschung. 1996;46:716–719.

    CAS  PubMed  Google Scholar 

  15. Wagner JG. Pharmacokinetic absorption plots from oral data alone or oral/intravenous data and an exact Loo-Riegelman equation. J Pharm Sci. 1983;72:838–842.

    Article  CAS  PubMed  Google Scholar 

  16. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker Inc, 1982.

    Google Scholar 

  17. Pharsight Corporation Winnonlin. Professional ed 2.1. Pharsight Corporation, 299 California Avenue, Palo Alto, CA; 1998.

  18. SPSS for Windows [computer program]. Release 10.0.5, standard version. Chicago, Illinois: SPSS Inc; 1999.

  19. el Mansouri S, Tod M, Leclerq M, Petitjean O, Perret G, Porthault M. Time-and dose-dependent kinetics of all-trans-retinoic acid in rats after oral or intravenous administration(s). Drug Metab Dispos. 1995;23:227–231.

    PubMed  Google Scholar 

  20. Adamson PC, Balis FM, Smith MA, Murphy RF, Godwin KA, Poplack DG. Dose-dependent pharmacokinetics of all-trans-retinoic acid. J Natl Cancer Inst. 1992;84(17):1332–1335.

    Article  CAS  PubMed  Google Scholar 

  21. Adamson PC. Pharmacokinetics of all-trans retinoic acid: clinical implications in acute promyelocytic leukemia. Semin Hematol. 1994;31:14–17.

    CAS  PubMed  Google Scholar 

  22. Wang Y, Zolfaghari R, Ross AC. Cloning of rat cytochrome P450RAI (CYP26) cDNA and regulation of its gene expression by all-trans-retinoic acid in vivo. Arch Biochem Biophys. 2002;401:235–243.

    Article  CAS  PubMed  Google Scholar 

  23. Ozpolat B, Lopez-Berestein G, Admason P, Fu CJ, Williams AH. Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers. J Pharm Pharm Sci. [serial online] 2003;6:292–301. Available at: www.ualberta.ca/∼csps. Accessed October 22, 2003.

    CAS  Google Scholar 

  24. Lampen A, Meyer S, Nau H. Effects of receptor-selective retinoids on cyp 26 gene expression and metabolism of all-tras-retinoic acid in intestinal cell. Drug Metab Dispos. 2001;29:742–747.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to José-Esteban Peris.

Additional information

Published: January 9, 2004

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saadeddin, A., Torres-Molina, F., Cárcel-Trullols, J. et al. Pharmacokinetics of the time-dependent elimination of all-trans-retinoic acid in rats. AAPS J 6, 1 (2004). https://doi.org/10.1208/ps060101

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/ps060101

Keywords

Navigation